Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association Writing Group.
- 1 December 1994
- journal article
- guideline
- Published by Wolters Kluwer Health in Circulation
- Vol. 90 (6) , 3125-3133
- https://doi.org/10.1161/01.cir.90.6.3125
Abstract
No abstract availableThis publication has 48 references indexed in Scilit:
- Prevention of restenosis by lovastatin after successful coronary angioplastyAmerican Heart Journal, 1991
- Reduction in the Rate of Early Restenosis after Coronary Angioplasty by a Diet Supplemented with n–3 Fatty AcidsNew England Journal of Medicine, 1988
- Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1988
- Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1988
- DipyridamoleNew England Journal of Medicine, 1987
- Long-Term Follow-up after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1987
- Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients: Summary results of the recurrent coronary prevention projectAmerican Heart Journal, 1986
- Effect of Dipyridamole and Aspirin on Late Vein-Graft Patency after Coronary Bypass OperationsNew England Journal of Medicine, 1984
- A Platelet-Inhibitor-Drug Trial in Coronary-Artery Bypass OperationsNew England Journal of Medicine, 1982
- Aortocoronary bypass saphenous vein graft atherosclerosis: Anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months postoperativelyThe American Journal of Cardiology, 1977